- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
ETF Trends reported that healthcare exchange-traded funds (ETFs) could receive a boost if “some heavily shorted health care stocks” rally as the year draws to a close, prompting short covering.
ETF Trends reported that healthcare exchange-traded funds (ETFs) could receive a boost if “some heavily shorted health care stocks” rally as the year draws to a close, prompting short covering. Biotechnology ETFs in particular could benefit.
As quoted in the market news:
Although pharmaceuticals stocks and ETFs have … been stellar performers, short interest at the end of last month for Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) was $1.9 billion apiece, according to FactSet. For Johnson & Johnson (NYSE: JNJ) and Eli Lilly (NYSE: LLY) short interest at the end of October was $2.7 billion and $1.8 billion, respectively. Short interest in Merck (NYSE: MRK), like J&J and Pfizer a Dow component, was $1.7 billion, according to FactSet.
Those pharmaceuticals stocks combine for 23% of the PowerShares Dynamic Pharmaceuticals Portfolio (NYSEArca: PJP), one of this year’s top-10 sector ETFs. PJP, which is up 26.2% this year, also features solid biotech exposure, meaning it could benefit from potential short covering of those stocks.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.